Phase 2 N=175 A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
Influenza
Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=241 Flublok or Fluzone With Advax-CpG55.2 or AF03
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Phase 4 N=1,000 A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Influenza Vaccines
Primary: Geometric Mean Titers (GMTs) of Anti-H3 and B Strains — 369.6; 331.2; 269.6; 245.0 Titer
Phase 4 N=120 Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Fluzone® Vaccination — 40; 10; 4; 6 Participants
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 2 N=102 Influenza Vaccine in Pregnant Women
Influenza
Primary: Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against Each Antigen Included in the 2008-2009…
Phase 4 N=120 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Influenza
Primary: Number of Participants With at Least 1 Solicited Injection Site Solicited Systemic Reactions Post-vaccination With Fluzone® Vaccine. — 35; 18; 34; 16 Participants
Phase 4 N=200 Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® or Fluzone® Intradermal or Fluzone® High-Dose…
Phase 1 N=63 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Phase 2 N=183 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
Influenza
Primary: Number of Participants Reporting Vaccine-associated Unsolicited Non-serious Adverse Events — 2; 3; 2; 0 participants
Phase 4 N=120 Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres
Phase 4 N=984 Inactivated Influenza Via Jet Injection
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3
Influenza, Human
Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent…
Phase 2 N=63 Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
Seasonal Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Phase 4 N=1,952 Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Phase 4 N=465 Immunologic Response to FluMist vs. Flucelvax
Influenza, Human · Immune Response
Primary: Number of Participants With Seroconversion Response In 2019 — 5; 33; 11; 44 Participants — p=<0.001
Phase 3 N=120 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 61.0; 65.7; 337.4; 207.5 Titer
Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 4 N=121 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Influenza
Primary: Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone® — 15; 7; 0; 2 Percentage of Participants
Phase 4 N=120 Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
Influenza
Primary: Percentage of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination — 60; 23; 8; 5 Percentage of Participants
N/A N=2,776,278 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
Influenza · Pneumonia · Lower Respiratory Tract Infection
Primary: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests — 559; 925 participants — p=<0.05
Phase 4 N=757 FLUAD® vs. Fluzone® High-Dose Study
Pain · Quality of Life · Injection Site Reaction
Primary: Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1 — 297; 282; 69; 73 Participants
N/A N=48 Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
Phase 2 N=817 Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Number of Participants With at Least a 4-Fold Increase in Serum HAI Antibody Titer Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine…
Phase 2 N=2,098 Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine. — 18.3; 18.6; 17.8; 17.3 Titers